The sudden and unexpected appearance of inhibitors in a previously treated severe haemophilia B patient after the switch to albutrepenonacog alpha

Haemophilia. 2018 Sep;24(5):e372-e375. doi: 10.1111/hae.13590. Epub 2018 Aug 8.

Authors

Ezio Zanon¹, Samantha Pasca¹, Paolo Simioni²

Affiliations

¹ Hemophilia Center, University Hospital of Padua, Padova, Italy.
² Hemorrhagic and Thrombotic Diseases, University Hospital of Padua, Padova, Italy.

PMID: 30088312
DOI: 10.1111/hae.13590

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Blood Coagulation Factor Inhibitors / blood
Drug Dosage Calculations
Drug Substitution / adverse effects
Factor IX / adverse effects
Factor IX / pharmacokinetics
Factor IX / therapeutic use*
Hematoma / diagnosis*
Hematoma / drug therapy
Hematoma / etiology
Hemophilia A / complications
Hemophilia A / drug therapy*
Hemophilia B / complications
Hemophilia B / drug therapy*
Humans
Joint Diseases / etiology
Joint Diseases / prevention & control*
Male
Recombinant Fusion Proteins / adverse effects
Recombinant Fusion Proteins / pharmacokinetics
Recombinant Fusion Proteins / therapeutic use*
Serum Albumin / adverse effects
Serum Albumin / pharmacokinetics
Serum Albumin / therapeutic use*
Young Adult

Substances

Blood Coagulation Factor Inhibitors
Recombinant Fusion Proteins
Serum Albumin
Factor IX
albutrepenonacog alfa